Gestogen intrauterine hormonal contraception in women of senior reproductive age


Cite item

Full Text

Abstract

Hormonal contraception, because of the numerous beneficial effects is always used not only for protection against unwanted pregnancy, but also as means of treating a variety of gynecological diseases. Enthusiasm for curative aspects of hormonal contraceptives has led to a shift in emphasis on therapeutic practice and underuse of preventive potential of contraceptive hormones. This particularly refers to the management of women of seniorreproductive group repositories in premenopausal and perimenopausal age. In this group the leading role is left to the questions of treating disorders associated with the extinction of ovarian functions including abnormal uterine bleeding, and substitution of estrogen deficiency, while the problem of birth control tends to be overshadowed. Reduced fertility in this age period should not be an argument for abandoning contraception, especially taking into consideration the fact that timely administration of contraceptive will not heal, but prevent the development of similar violations, which subsequently become an indication for therapeutic purpose of contraceptive hormones. Dual prevention, including the prevention of unwanted pregnancies and prevention of gynecological diseases associated with aging of the reproductive system is the basis for the selection of effective, timely and safe contraception with additional healing properties for women entering into physiological premenopausal period.

About the authors

I V Kuznetsova

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России

Email: ms_smith@list.ru
д-р мед. наук, проф., гл. науч. сотр. НИО женского здоровья НОКЦ женского здоровья

References

  1. World Contraceptive Use 2003 United Nations Department of Economic and Social Affairs Population Division.
  2. Прилепская В.Н. Руководство по контрацепции. М: МЕДпресс - информ, 2006.
  3. Jensen J.T, Parke S, Mellinger U et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomizedcontrolled trial. Obstet Gynecol 2011; 117: 777–87.
  4. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews Meta-Analysis 2012; 7: CD004143.
  5. Freeman E.W, Halbreich U, Grubb G.S et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 2012; 85: 437–45.
  6. Sulak P, Willis S, Kuehl T et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47: 27–37.
  7. Edelman A.B, Gallo M.F, Jensen J.T et al. Continuousor extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2005; 3: CD004695.
  8. Speroff L, Darney P.D. A clinical guide for contraception. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
  9. Alexander N.J, Baker E, Kaptein M et al. Why consider vaginal drug administration? Fertil Steril 2004; 82: 1–12.
  10. Медицинские критерии приемлемости методов контрацепции РФ. 2012: 242.
  11. Curtis K.M, Jamieson D.J, Peterson H.B, Marchbanks P.A. Adaptation of the World Health Organization’s medical eligibility criteria for contraceptive use for use in the United States. Contraception 2010; 82: 3–9.
  12. Jensen J.T. Evaluation of a new estradiol oral contraceptive: estradiol valerte and dienogest. Exp Opin Pharm 2010; 11:1147–57.
  13. Finer L.B, Zolna M.R. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84: 478–85.
  14. Pazol K, Creanga A.A, Zane S.B et al. Abortion surveillance – United States, 2009. MMWR Surveillance Summaries 2012; 61 (8): 1–44.
  15. Pal L, Santoro N. Age - related decline in fertility. Endocrin Metab Clin NA 2003; 32 (3): 669–88.
  16. Callaghan W.M. Overview of maternal mortality in the United States. Sem Perinatol 2012; 36 (1): 2–6.
  17. Jacobsson B, Ladfors L, Milsom I. Advanced maternal age and adverse perinatal outcome. Obstet Gynecol 2004; 104 (4): 727–33.
  18. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75 (Suppl. 6): S70–75.
  19. Sherman C.A, Harvey S.M, Noell J. Are they still having sex? STI’s and unintended pregnancy among midlife women. J Women Aging 2005; 17 (3): 41–55.
  20. Endrikat J, Gerlinger C, Richard S et al. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception 2011; 84 (6): 549–57.
  21. Shoupe D. Contraception. Chichester, West Sussex: Wiley–Blackwell; 2011.
  22. Isley M.M, Kaunitz A.M. Update on hormonal contraception and bone density. Rev Endocr Metab Dis 2011; 12 (2): 93–106.
  23. Xu H, Wade J.A, Peipert J.F et al. Contraceptive failurerates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120 (1): 21–6.
  24. Grant L. Treatment of perimenopausal menorrhagia with Implanon. J Fam Plan Reprod Health Care 2008; 34 (4): 274.
  25. Peipert J.F, Zhao Q, Allsworth J.E et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117 (5): 1105–13.
  26. Lethaby A.E, Cooke I, Rees M. Progesterone or progestogen - releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2005; 4: CD002126.
  27. Milsom I. The levonorgestrel - releasing intrauterine system as an alternative to hysterectomy in perimenopausal women. Contraception 2007; 75 (Suppl. 6): S152–154.
  28. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri - and postmenopausal women. Contraception 2007; 75 (Suppl. 6): S155–160.
  29. A new low - dose levonorgestrel - releasing IUD (Skyla). Med Lett Drugs Ther 2013; 55 (1412): 21–2.
  30. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrel - releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta - analysis. Menopause 2011; 18 (10): 1060–6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).